Voriconazole, Quantitation by LC-MS/MS

Also known as: VORICON AF

Clinical Use

Use

Voriconazole is an azole antifungal drug indicated to treat invasive aspergillosis, candidiasis, scedosporiosis, and fusariosis infections. The therapeutic range is determined based on serum, predose (trough) draw collection at steady-state concentration, which is crucial for optimizing drug therapy and monitoring patient adherence. The pharmacokinetics of voriconazole are influenced by drug-drug interactions, particularly when coadministered with drugs metabolized by cytochrome P450 2C9, 2C19, and 3A4 enzymes, which underscores the importance of this test in therapeutic drug monitoring.

Special Instructions

Not provided.

Limitations

This is a laboratory-developed test and has not been cleared or approved by the US Food and Drug Administration. As such, it is intended solely for clinical purposes performed in a CLIA certified laboratory. Analytical performance may vary, and physicians should interpret results considering the entire clinical context of the patient. Adverse effects of voriconazole may include nausea, vomiting, tachycardia, and elevated serum liver enzymes.

Test Details

New York Approved

Methodology

Mass Spectrometry

Biomarkers

Voriconazole

Analyte

Voriconazole level

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Order Codes

38370-3 - Voriconazole SerPl-mCnc

Result Turnaround Time

1-6 days

Specimen

Serum

Volume

1 mL

Minimum Volume

0.6 mL

Container

ARUP Standard Transport Tube

Collection Instructions

Separate from cells ASAP or within 2 hours of collection. Transfer to the transport tube.

Patient Preparation

Specimens collected just before or within 15 minutes of the next dose represent the TROUGH levels. Specimens obtained within specific times post administration represent the PEAK level. Collect pre-dose (trough) at steady state concentration.